F-group (family)
109.4.1.1 14-3-3
Ligands and drugs
1,297
Member domains
778
with ligand contacts (≤ 4 Å)
60.0% of members
673
with DrugDomain annotations
51.9% of members
267
with a DrugBank compound
20.6% of members
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
Chemical profiles are computed for X-groups. 109.4.1.1 belongs to X-group 109 Repetitive alpha hairpins, which binds 9.1 ligand superclasses per 20 proteins, broader than 82% of the 256 X-groups with enough proteins to compare. View its chemical profile →
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB01780 | FSC | Fusicoccin | 35 |
| DB03793 | BEZ | Benzoic acid | 26 |
| DB02676 | B3P | 2-[3-(2-Hydroxy-1,1-Dihydroxymethyl-Ethylamino)-Propylamino]-2-Hydroxymethyl-Propane-1,3-Diol | 16 |
| DB00141 | NAG | N-Acetylglucosamine | 12 |
| DB12695 | — | — | 5 |
| DB00125 | ARG | Arginine | 4 |
| DB00130 | GLN | L-Glutamine | 4 |
| DB01694 | TAR | D-tartaric acid | 4 |
| DB04332 | ETE | 2-{2-[2-2-(Methoxy-Ethoxy)-Ethoxy]-Ethoxy}-Ethanol | 4 |
| DB00135 | TYR | Tyrosine | 3 |
| DB02175 | MLA | Malonic acid | 3 |
| DB03345 | BME | Mercaptoethanol | 3 |
| DB03226 | ETF | Trifluoroethanol | 2 |
| DB03766 | PPI | Propanoic acid | 2 |
| DB03900 | TBU | tert-butanol | 2 |
| DB00114 | PLP | Pyridoxal phosphate | 1 |
| DB00131 | AMP | Adenosine phosphate | 1 |
| DB00936 | SAL | Salicylic acid | 1 |
| DB03309 | NHE | N-cyclohexyltaurine | 1 |
| DB04522 | SEP | Dexfosfoserine | 1 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| MGmetal | MAGNESIUM ION | 335 |
| CL | CHLORIDE ION | 299 |
| CAmetal | CALCIUM ION | 121 |
| NAmetal | SODIUM ION | 41 |
| FSC | FUSICOCCIN | 36 |
| BEZ | BENZOIC ACID | 29 |
| B3P | 2-[3-(2-HYDROXY-1,1-DIHYDROXYMETHYL-ETHYLAMINO)-PROPYLAMINO]-2-HYDROXYMETHYL-PROPANE-1,3-DIOL | 17 |
| NAG | 2-acetamido-2-deoxy-beta-D-glucopyranose | 12 |
| CFH | 1,1,1,3,3,3-hexafluoropropan-2-ol | 9 |
| 9SZ | (1R,5S,9S,16R,20R,24S,28S,35R)-3,22-Bis(dihydroxyphosphoryloxy)tridecacyclo[22.14.1.15,20.19,16.128,35.02,23.04,21.06,19.08,17.010,15.025,38.027,36.029,34]dotetraconta-2(23),3,6,8(17),10,12,14,18,21,25,27(36),29,31,33,37-pentadecaene | 8 |
| CDmetal | CADMIUM ION | 8 |
| UNX | UNKNOWN ATOM OR ION | 8 |
| WQI | 2-chloranyl-~{N}-[[1-(4-iodophenyl)sulfonylpiperidin-4-yl]methyl]ethanamide | 8 |
| WQ9 | 1-[(5~{R})-2-(4-bromanyl-3-fluoranyl-phenyl)sulfonyl-2,7-diazaspiro[4.4]nonan-7-yl]-2-chloranyl-ethanone | 6 |
| 09W | ~{N}-[(5-carbamimidoyl-3-phenyl-thiophen-2-yl)methyl]-2,3-dihydro-1-benzofuran-7-carboxamide | 5 |
| 0AW | ~{N}-[(5-carbamimidoyl-3-phenyl-thiophen-2-yl)methyl]-2,3-dihydro-1-benzofuran-5-carboxamide | 5 |
| AMP | ADENOSINE MONOPHOSPHATE | 5 |
| GEH | 2-(4-chloranylphenoxy)-2-methyl-~{N}-(2-sulfanylethyl)propanamide | 5 |
| WPN | ~{N}-[[1-(4-bromophenyl)sulfonylpiperidin-4-yl]methyl]-2-chloranyl-ethanamide | 5 |
| WQN | 1-[8-(4-bromophenyl)sulfonyl-5-oxa-2,8-diazaspiro[3.5]nonan-2-yl]-2-chloranyl-ethanone | 5 |